Name /VISEN Pharmaceuticals (Taiwan) Ltd.
Address /7F, No. 2, Section 3, Minsheng E Rd, Zhongshan District, Taipei City, Taiwan 10491
Website / www.visenpharma.com.tw
Name /Popo Lin
Title /VP of Taiwan Operation
VISEN is an innovative biopharmaceutical company focused on endocrine diseases. We are dedicated to providing innovative therapies and compassionate, patient-centric care, because we believe that achieving better treatment processes and outcomes results in living better lives. Putting patients’ need first, VISEN is committed to providing first-in-class or best-in-class products and treatments for endocrine diseases. Our therapeutic areas cover endocrine diseases in adults and children, and rare endocrine diseases.
VISEN comprises seasoned professionals with multinational pharmaceutical experiences and leverages cutting-edge technologies and leading resources across the world. We are focused on the Greater China market, with established offices in Shanghai, Beijing, Hong Kong and Taipei. We have also launched our Greater China R&D and manufacturing site in Suzhou to enhance R&D, manufacturing and commercialization efforts. Our goal is to enable endocrine patients to benefit from the world's most advanced and reliable treatment solutions earlier.
VISEN has a robust pipeline of potential endocrinology product candidates. Our pipeline includes long-acting growth hormone, hypoparathyroidism, and achondroplasia.
All the products are based on TransCon: an innovative technology platform for drug development. TransCon refers to “transient conjugation”, or our unique ability to temporarily (transiently) link an inert carrier to a parent drug with known biology.
Depending on the carrier used, TransCon prodrugs can be designed to act systemically (throughout the body) or locally (e.g. intratumorally), focused on meeting a specific therapeutic goal. TransCon is widely applicable to proteins, peptides or small molecules in multiple therapeutic areas.
TransCon combines known biology with the benefits of prodrug and sustained-release technologies to potentially optimize therapeutic effect. This could mean enhancing efficacy, improving tolerability and convenience, or reducing caregiver burden.
Name /Amber Wu